Akio Moriya
Okayama University
43 Papers
160 Citations
Akio Moriya is an academic researcher from Okayama University. The author has contributed to research in topics: Fatty liver & Hepatocellular carcinoma. The author has an hindex of 11, co-authored 38 publications.
Chat about Author
Papers
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan
Hidenori Toyoda,Masanori Atsukawa,Koichi Takaguchi,Tomonori Senoh,Kojiro Michitaka,Atsushi Hiraoka,Shinichi Fujioka,Chisa Kondo,Tomomi Okubo,Haruki Uojima,Toshifumi Tada,Hirohito Yoneyama,Tsunamasa Watanabe,Toru Asano,Toru Ishikawa,Hideyuki Tamai,Hiroshi Abe,Keizo Kato,Kunihiko Tsuji,Chikara Ogawa,Noritomo Shimada,Etsuko Iio,Akihiro Deguchi,Ei Itobayashi,Shigeru Mikami,Akio Moriya,Hironao Okubo,Joji Tani,Akihito Tsubota,Yasuhito Tanaka,Tsutomu Masaki,Katsuhiko Iwakiri,Takashi Kumada +32 more
TL;DR: The EBR/GZR regimen yielded high virological efficacy with acceptable safety and patients with a history of failure to IFN-free DAA therapy or with double RASs in HCV-NS5A remained difficult to treat with this regimen.
29
Long‐term monitoring of platelet count, as a non‐invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy
Hideaki Taniguchi,Yoshiaki Iwasaki,Akiko Fujiwara,Kohsaku Sakaguchi,Akio Moriya,Piao Cheng Yu,Akinobu Takaki,Shin Ichi Fujioka,Hiroyuki Shimomura,Yasushi Shiratori +9 more
TL;DR: The aim of the present study was to assess hepatic fibrosis progression or regression of CHC patients by long‐term monitoring of the platelet count.
27
Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection
Hidenori Toyoda,Masanori Atsukawa,Tsunamasa Watanabe,Makoto Nakamuta,Haruki Uojima,Akito Nozaki,Koichi Takaguchi,Shinichi Fujioka,Etsuko Iio,Toshihide Shima,Takehiro Akahane,Shinya Fukunishi,Toru Asano,Kojiro Michitaka,Kunihiko Tsuji,Hiroshi Abe,Shigeru Mikami,Hironao Okubo,Tomomi Okubo,Noritomo Shimada,Toru Ishikawa,Akio Moriya,Joji Tani,Asahiro Morishita,Chikara Ogawa,Yoshihiko Tachi,Hiroki Ikeda,Naoki Yamashita,Satoshi Yasuda,Makoto Chuma,Akemi Tsutsui,Atsushi Hiraoka,Tadashi Ikegami,Takuya Genda,Akihito Tsubota,Tsutomu Masaki,Yasuhito Tanaka,Katsuhiko Iwakiri,Takashi Kumada +38 more
TL;DR: This study sought to confirm findings in real‐world settings, focusing on patients with cirrhosis, history of DAA failure, or HCV genotype 3 who were treated with a 12‐week regimen in a large multicenter study from Japan.
26
A target-controlled infusion system with bispectral index monitoring of propofol sedation during endoscopic submucosal dissection.
Atsushi Imagawa,Hidenori Hata,Morihito Nakatsu,Akihiro Matsumi,Eijiro Ueta,Kozue Suto,Hiroyuki Terasawa,Hiroyuki Sakae,Keiko Takeuchi,Manabu Fujihara,Hitomi Endo,Hisae Yasuhara,Shinichi Ishihara,Hiromitsu Kanzaki,Hideki Jinno,Hidenori Kamada,Eisuke Kaji,Akio Moriya,Masaharu Ando +18 more
TL;DR: It is possible for a non-anesthesiologist to maintain stable sedation during a lengthy endoscopic procedure through propofol sedation with a BIS/TCI system.
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
Asahiro Morishita,Kyoko Oura,Kei Takuma,Mai Nakahara,Tomoko Tadokoro,Koji Fujita,Joji Tani,Tingting Shi,Takashi Himoto,Miwa Tatsuta,Akio Moriya,Tomonori Senoo,Akemi Tsutsui,Takuya Nagano,Koichi Takaguchi,Masafumi Ono,Tsutomu Masaki +16 more
TL;DR: In this article , the effect of pemafibrate treatment on liver function and fibrosis by liver function tests (LFTs) and various fibrotic biomarkers including FibroScan in non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia.